Show simple item record

dc.contributor.authorVelasco-de Andrés, María
dc.contributor.authorCatalà, Cristina
dc.contributor.authorCasadó-Llombart, Sergi
dc.contributor.authorMartínez-Florensa, Mario
dc.contributor.authorSimões, Inês
dc.contributor.authorGarcía-Luna, Joaquín
dc.contributor.authorMourglia-Ettlin, Gustavo
dc.contributor.authorZaragoza, Oscar 
dc.contributor.authorCarreras, Esther
dc.contributor.authorLozano, Francisco
dc.date.accessioned2020-12-01T07:48:56Z
dc.date.available2020-12-01T07:48:56Z
dc.date.issued2020-10-12
dc.identifier.citationAntimicrob Agents Chemother. 2020 Dec 16;65(1):e01103-20.es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11476
dc.description.abstractBackground: Invasive fungal diseases represent an unmet clinical need that could benefit from novel immunotherapeutic approaches. Host pattern-recognition receptors (e.g., Toll-like receptors, C-type lectins or Scavenger receptors) that sense conserved fungal cell wall constituents may provide suitable immunotherapeutic antifungal agents. Thus, we explored the therapeutic potential of the lymphocyte class I scavenger receptor CD5, a non-redundant component of the antifungal host immune response that binds to fungal β-glucans.Methods: antifungal properties of the soluble ectodomain of human CD5 (shCD5) were assessed in vivo in experimental models of systemic fungal infection induced by pathogenic species (Candida albicans and Cryptococcus neoformans). In vitro mechanistic studies were performed by means of fungal-spleen cell co-cultures.Results: shCD5-induced survival of lethally infected mice was dose and time-dependent and concomitant with reduced fungal load and increased leukocyte infiltration in primary target organ. Additive effects were observed in vivo after shCD5 was combined with sub-optimal doses of fluconazole. Ex vivo addition of shCD5 to fungal-spleen cell co-cultures increased release of pro-inflammatory cytokines involved in antifungal defence (TNF-α and IFN-γ) and reduced the number of viable C. albicansConclusions: The results prompt further exploration of the adjunctive therapeutic potential of shCD5 in severe invasive fungal diseases.es_ES
dc.description.sponsorshipThis work was supported by Spanish Ministerio de Economía y Competitividad (MINECO;SAF-2016-80535-R,PID2019-106658RB-I00 and PCIN-2015-070 to FL; SAF2017-86912-R to OZ) co-financed by European Development Regional Fund“A wa to achieve Europe” ERDF, and Agència de Gestió d’Ajuts Universitari side Recerca (AGAUR;2017/SGR/1582) from Generalitat de Catalunya. MV-dA,CC,SC- L,IS,JG- and EC are recipients of fellowships from Spanish MINECO (BES-2014-406069237; BES-2017-082107), Spanish Ministerio de Educación, Cultura y Deporte (FPU15/02897), Portuguese Fundação para a Ciênciae a Tecnologia (SFRH/BD/75738/2011), Uruguay an Agencia Nacional de Investigación e Innovación 409(POS-FCE-2018-1-1007796), and European Community Seventh Framework Program (BIOTRACK,FP7/2007/2013;229673), respectivelyes_ES
dc.language.isoenges_ES
dc.publisherAmerican Society for Microbiology (ASM) es_ES
dc.relation.isversionofPostprintes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectScavengerreceptores_ES
dc.subjectCD5es_ES
dc.subjectImmunotherapyes_ES
dc.subjectβ-glucanes_ES
dc.subjectFungalinfectiones_ES
dc.subjectCandidaalbicanses_ES
dc.subjectCryptococcusneoformanses_ES
dc.subjectFluconazolees_ES
dc.titleThe lymphocytic scavenger receptor CD5 shows therapeutic potential in mouse models of fungal infection.es_ES
dc.typeArtículoes_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID33046489es_ES
dc.identifier.doi10.1128/AAC.01103-20es_ES
dc.contributor.funderMinisterio de Economía y Competitividad (España)
dc.contributor.funderEuropean Regional Development Fund 
dc.contributor.funderGeneralitat de Catalunya
dc.contributor.funderFundação para a Ciência e a Tecnologia (Portugal)
dc.contributor.funderUnión Europea. Comisión Europea. 7 Programa Marco
dc.description.peerreviewedes_ES
dc.identifier.e-issn1098-6596
dc.relation.publisherversionhttp://dx.doi.org/ 10.1128/AAC.01103-20es_ES
dc.identifier.journalAntimicrobial agents and chemotherapyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ESSAF-2016-80535-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PID2019-106658RB-I00es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/PCIN-2015-070es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/SAF2017-86912-Res_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/AGAUR;2017/SGR/1582es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/BES-2014-40606923B7es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/BES-2017-082107es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/FPU15/02897es_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/EC/FP7/229673es_ES
dc.rights.accessRightsinfo:eu-repo/semantics/embargoedAccesses_ES


Files in this item

Acceso Abierto
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-CompartirIgual 4.0 Internacional
This item is licensed under a: Atribución-NoComercial-CompartirIgual 4.0 Internacional